Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6070 and ifinatamab deruxtecan-based regimens in first-line extensive-stage small cell lung cancer
2025-521032-11-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of gocatamig and ifinatamab deruxtecan in small cell lung cancer (SCLC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event, Number of participants who experience one or more dose-limiting toxicities and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
gocatamigifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-521032-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521032-11-00.